TY - JOUR
T1 - Sustained low-dose growth hormone therapy optimizes bioactive insulin-like growth factor-I level and may enhance CD4 T-cell number in HIV infection
AU - Andersen, Ove
AU - Hansen, Birgitte Rønde
AU - Troensegaard, William
AU - Flyvbjerg, Allan
AU - Madsbad, Sten
AU - Ørskov, Hans
AU - Nielsen, Jens Ole
AU - Iversen, Johan
AU - Haugaard, Steen B
N1 - (c) 2009 Wiley-Liss, Inc.
PY - 2010/2
Y1 - 2010/2
N2 - High-dose recombinant human growth hormone (rhGH) (2-6 mg/day) regimes may facilitate T-cell restoration in patients infected with human immunodeficiency virus (HIV) on highly active antiretroviral therapy (HAART). However, high-dose rhGH regimens increase insulin-like growth factor-I (IGF-I) to supra-physiological levels associated with severe side effects. The present study investigated whether lower doses of rhGH may improve T-cell restoration in patients infected with HIV following an expedient response of total and bioactive (i.e., free) IGF-I. A previous 16-week pilot-study included six HIV-infected patients on stable HAART to receive rhGH 0.7 mg/day, which increased total (+117%, P<0.01) and free (+155%, P<0.01) IGF-I levels. The study was extended to examine whether continuous use of low-dose rhGH (0.7 mg/day until week 60; 0.4 mg/day from week 60 to week 140) would maintain expedient IGF-I levels and improve CD4 T-cell response. Total and free IGF-I increased at week 36 (+97%, P<0.01 and +125%, P<0.01, respectively) and week 60 (+77%, P=0.01 and +125%, P<0.01) compared to baseline levels (161±15 and 0.75±0.11 μg/L).CD4T-cellnumber increased at week 36 (+15%, P <0.05) and week 60 (+31%, P=0.01) compared to baseline levels (456±55 cells/μL). Following rhGH dose reduction, total IGF-I and CD4 T-cell number remained increased at week 88 (+44%, P=0.01 and +33%, P <0.01) and week 140 (+46%, P=0.07 and +36%, P=0.02) compared to baseline levels. These data support the notion that low-dose rhGH regimens may increase expediently total and bioactive IGF-I and improve T-cell restoration in patients infected with HIV on HAART.
AB - High-dose recombinant human growth hormone (rhGH) (2-6 mg/day) regimes may facilitate T-cell restoration in patients infected with human immunodeficiency virus (HIV) on highly active antiretroviral therapy (HAART). However, high-dose rhGH regimens increase insulin-like growth factor-I (IGF-I) to supra-physiological levels associated with severe side effects. The present study investigated whether lower doses of rhGH may improve T-cell restoration in patients infected with HIV following an expedient response of total and bioactive (i.e., free) IGF-I. A previous 16-week pilot-study included six HIV-infected patients on stable HAART to receive rhGH 0.7 mg/day, which increased total (+117%, P<0.01) and free (+155%, P<0.01) IGF-I levels. The study was extended to examine whether continuous use of low-dose rhGH (0.7 mg/day until week 60; 0.4 mg/day from week 60 to week 140) would maintain expedient IGF-I levels and improve CD4 T-cell response. Total and free IGF-I increased at week 36 (+97%, P<0.01 and +125%, P<0.01, respectively) and week 60 (+77%, P=0.01 and +125%, P<0.01) compared to baseline levels (161±15 and 0.75±0.11 μg/L).CD4T-cellnumber increased at week 36 (+15%, P <0.05) and week 60 (+31%, P=0.01) compared to baseline levels (456±55 cells/μL). Following rhGH dose reduction, total IGF-I and CD4 T-cell number remained increased at week 88 (+44%, P=0.01 and +33%, P <0.01) and week 140 (+46%, P=0.07 and +36%, P=0.02) compared to baseline levels. These data support the notion that low-dose rhGH regimens may increase expediently total and bioactive IGF-I and improve T-cell restoration in patients infected with HIV on HAART.
U2 - 10.1002/jmv.21625
DO - 10.1002/jmv.21625
M3 - Journal article
SN - 0146-6615
VL - 82
SP - 197
EP - 205
JO - Journal of Medical Virology
JF - Journal of Medical Virology
IS - 2
ER -
